Nuwiq

Country: Kesatuan Eropah

Bahasa: Inggeris

Sumber: EMA (European Medicines Agency)

Beli sekarang

Risalah maklumat Risalah maklumat (PIL)
07-11-2022
Ciri produk Ciri produk (SPC)
07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam (PAR)
17-01-2018

Bahan aktif:

simoctocog alfa

Boleh didapati daripada:

Octapharma AB

Kod ATC:

B02BD02

INN (Nama Antarabangsa):

simoctocog alfa

Kumpulan terapeutik:

Blood coagulation factors

Kawasan terapeutik:

Hemophilia A

Tanda-tanda terapeutik:

Treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency).Nuwiq can be used for all age groups.

Ringkasan produk:

Revision: 13

Status kebenaran:

Authorised

Tarikh kebenaran:

2014-07-22

Risalah maklumat

                                45
B. PACKAGE LEAFLET
46
PACKAGE LEAFLET: INFORMATION FOR THE USER
NUWIQ 250 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
NUWIQ 500 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
NUWIQ 1000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
NUWIQ 1500 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
NUWIQ 2000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
NUWIQ 2500 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
NUWIQ 3000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
NUWIQ 4000 IU POWDER AND SOLVENT FOR SOLUTION FOR INJECTION
simoctocog alfa (recombinant human coagulation factor VIII)
READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START USING THIS
MEDICINE BECAUSE IT CONTAINS
IMPORTANT INFORMATION FOR YOU.
-
Keep this leaflet. You may need to read it again.
-
If you have any further questions, ask your doctor.
-
This medicine has been prescribed for you only. Do not pass it on to
others. It may harm them,
even if their signs of illness are the same as yours.
-
If you get any side effects, talk to your doctor. This includes any
possible side effects not listed
in this leaflet. See section 4.
WHAT IS IN THIS LEAFLET
1.
What Nuwiq is and what it is used for
2.
What you need to know before you use Nuwiq
3.
How to use Nuwiq
4.
Possible side effects
5.
How to store Nuwiq
6.
Contents of the pack and other information
1.
WHAT NUWIQ IS AND WHAT IT IS USED FOR
Nuwiq contains the active substance human recombinant coagulation
factor VIII (simoctocog alfa).
Factor VIII is necessary for the blood to form clots and stop
bleeding. In patients with haemophilia A
(inborn factor VIII deficiency), factor VIII is missing or not working
properly.
Nuwiq replaces the missing factor VIII and is used for treatment and
prevention of bleeding in patients
with haemophilia A and can be used for all age groups.
2.
WHAT YOU NEED TO KNOW BEFORE YOU USE NUWIQ
DO NOT USE NUWIQ
•
if you are allergic to the active substance simoctocog alfa or any of
the other ingredients of
this medicine (listed in section 6).
If you are unsure about 
                                
                                Baca dokumen lengkap
                                
                            

Ciri produk

                                1
ANNEX I
SUMMARY OF PRODUCT CHARACTERISTICS
2
1.
NAME OF THE MEDICINAL PRODUCT
Nuwiq 250 IU powder and solvent for solution for injection
Nuwiq 500 IU powder and solvent for solution for injection
Nuwiq 1000 IU powder and solvent for solution for injection
Nuwiq 1500 IU powder and solvent for solution for injection
Nuwiq 2000 IU powder and solvent for solution for injection
Nuwiq 2500 IU powder and solvent for solution for injection
Nuwiq 3000 IU powder and solvent for solution for injection
Nuwiq 4000 IU powder and solvent for solution for injection
2.
QUALITATIVE AND QUANTITATIVE COMPOSITION
Nuwiq 250 IU powder and solvent for solution for injection
Each vial contains nominally 250 IU human coagulation factor VIII
(rDNA), simoctocog alfa.
Nuwiq 250 IU contains approximately 100 IU/mL of human coagulation
factor VIII (rDNA),
simoctocog alfa after reconstitution.
Nuwiq 500 IU powder and solvent for solution for injection
Each vial contains nominally 500 IU human coagulation factor VIII
(rDNA), simoctocog alfa.
Nuwiq 500 IU contains approximately 200 IU/mL of human coagulation
factor VIII (rDNA),
simoctocog alfa after reconstitution.
Nuwiq 1000 IU powder and solvent for solution for injection
Each vial contains nominally 1000 IU human coagulation factor VIII
(rDNA), simoctocog alfa.
Nuwiq 1000 IU contains approximately 400 IU/mL of human coagulation
factor VIII (rDNA),
simoctocog alfa after reconstitution.
Nuwiq 1500 IU powder and solvent for solution for injection
Each vial contains nominally 1500 IU human coagulation factor VIII
(rDNA), simoctocog alfa.
Nuwiq 1500 IU contains approximately 600 IU/mL of human coagulation
factor VIII (rDNA),
simoctocog alfa after reconstitution.
Nuwiq 2000 IU powder and solvent for solution for injection
Each vial contains nominally 2000 IU human coagulation factor VIII
(rDNA), simoctocog alfa.
Nuwiq 2000 IU contains approximately 800 IU/mL of human coagulation
factor VIII (rDNA),
simoctocog alfa after reconstitution.
Nuwiq 2500 IU powder and solvent for solution for injection
Ea
                                
                                Baca dokumen lengkap
                                
                            

Dokumen dalam bahasa lain

Risalah maklumat Risalah maklumat Bulgaria 07-11-2022
Ciri produk Ciri produk Bulgaria 07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam Bulgaria 17-01-2018
Risalah maklumat Risalah maklumat Sepanyol 07-11-2022
Ciri produk Ciri produk Sepanyol 07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam Sepanyol 17-01-2018
Risalah maklumat Risalah maklumat Czech 07-11-2022
Ciri produk Ciri produk Czech 07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam Czech 17-01-2018
Risalah maklumat Risalah maklumat Denmark 07-11-2022
Ciri produk Ciri produk Denmark 07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam Denmark 17-01-2018
Risalah maklumat Risalah maklumat Jerman 07-11-2022
Ciri produk Ciri produk Jerman 07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam Jerman 17-01-2018
Risalah maklumat Risalah maklumat Estonia 07-11-2022
Ciri produk Ciri produk Estonia 07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam Estonia 17-01-2018
Risalah maklumat Risalah maklumat Greek 07-11-2022
Ciri produk Ciri produk Greek 07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam Greek 17-01-2018
Risalah maklumat Risalah maklumat Perancis 07-11-2022
Ciri produk Ciri produk Perancis 07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam Perancis 17-01-2018
Risalah maklumat Risalah maklumat Itali 07-11-2022
Ciri produk Ciri produk Itali 07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam Itali 17-01-2018
Risalah maklumat Risalah maklumat Latvia 07-11-2022
Ciri produk Ciri produk Latvia 07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam Latvia 17-01-2018
Risalah maklumat Risalah maklumat Lithuania 07-11-2022
Ciri produk Ciri produk Lithuania 07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam Lithuania 17-01-2018
Risalah maklumat Risalah maklumat Hungary 07-11-2022
Ciri produk Ciri produk Hungary 07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam Hungary 17-01-2018
Risalah maklumat Risalah maklumat Malta 07-11-2022
Ciri produk Ciri produk Malta 07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam Malta 17-01-2018
Risalah maklumat Risalah maklumat Belanda 07-11-2022
Ciri produk Ciri produk Belanda 07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam Belanda 17-01-2018
Risalah maklumat Risalah maklumat Poland 07-11-2022
Ciri produk Ciri produk Poland 07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam Poland 17-01-2018
Risalah maklumat Risalah maklumat Portugis 07-11-2022
Ciri produk Ciri produk Portugis 07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam Portugis 17-01-2018
Risalah maklumat Risalah maklumat Romania 07-11-2022
Ciri produk Ciri produk Romania 07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam Romania 17-01-2018
Risalah maklumat Risalah maklumat Slovak 07-11-2022
Ciri produk Ciri produk Slovak 07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam Slovak 17-01-2018
Risalah maklumat Risalah maklumat Slovenia 07-11-2022
Ciri produk Ciri produk Slovenia 07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam Slovenia 17-01-2018
Risalah maklumat Risalah maklumat Finland 07-11-2022
Ciri produk Ciri produk Finland 07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam Finland 17-01-2018
Risalah maklumat Risalah maklumat Sweden 07-11-2022
Ciri produk Ciri produk Sweden 07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam Sweden 17-01-2018
Risalah maklumat Risalah maklumat Norway 07-11-2022
Ciri produk Ciri produk Norway 07-11-2022
Risalah maklumat Risalah maklumat Iceland 07-11-2022
Ciri produk Ciri produk Iceland 07-11-2022
Risalah maklumat Risalah maklumat Croat 07-11-2022
Ciri produk Ciri produk Croat 07-11-2022
Laporan Penilaian Awam Laporan Penilaian Awam Croat 17-01-2018

Cari amaran yang berkaitan dengan produk ini

Lihat sejarah dokumen